A patent does not guaranty a commercializable product. How long has this company been fooling around with animal studies and Phase I clinical studies? It is now Jan 2013. 35.20 million outstanding stock and 19.3 million float. That after the gigantic reverse split. Lets see what these numbers are in Jan 2014 and how much progress with clinical studies. Also how many real employees, scientists and clinical related employees turn around!
Fred Knoll joined the BOD as well as financed the company. He has never joined a BOD prior to AHRO, even Medivation (MDVN) of which he owns I believe 15% or more. MDVN went from $8 to $110+. I'll take a chance on this one.
Good to know someone is supporting this stock. Stock will be $0.25 by the end of the year. Try asking Gardner what he has done in the past 10 years. How many years of experience in drugs? Smoking, injecting and inhaling don't count.
I met Tom Gardner at the Noble Financial Conference last week in Ft. Lauderdale. He presented for Atheronova and made an excellent persentation that was very well received. He's been CEO and Chairman at Atheronova for almost 7 years. He recently turned around a near-bankrupt ortho company and sold the assets at a 3X transaction at the minimum. AHRO is the fourth publicly traded company that he has founded. 2013 will be an important year for atheronova, and I'm a buyer.